Skip to main content
. Author manuscript; available in PMC: 2017 Mar 25.
Published in final edited form as: Dermatology. 2016 Mar 25;232(3):344–352. doi: 10.1159/000444580

Table 1.

Studies of prevalence rate of skin and skin-related disease using the REP, Olmsted County, Minn., USA

Reference Disease Age, years Date/period of prevalence estimate Prevalence
Shahi et al. [5] HS All Jan 1, 2009 127.8 (108.9–146.8)
Shbeeb et al. [6] Psoriasis ≥18 Jan 1, 1992 700.0 (650.0–750.0)
Shbeeb et al. [6] Psoriatic arthritis ≥18 Jan 1, 1992 101.0 (80.0–120.0)
Wilson et al. [7] Psoriatic arthritis All Jan 1, 2000 158.0 (132.0–185.0)
Calamia et al. [8] BD ≥18 2000 5.2 (0.64–9.84)
Bendewald et al. [9] DM All Jan 1, 2007 21.42 (13.07–29.77)
Michet et al. [10] Scleroderma All Jan 1, 1980 13.8 (4.2–23.4)
Kurland et al. [11] SLE All Jan 1, 1968 48.0
Michet et al. [10] SLE All Jan 1, 1980 40.0 (23.5–57.5)
Uramoto et al. [12] SLE All Jan 1, 1993 122.0 (97.0–147.0)
Jarukitsopa et al. [13] SLE All Jan 1, 2006 30.5 (21.1–39.9)
Michet et al. [10] Suspected SLE All Jan 1, 1980 32.8 (18.1–47.5)
Nobrega et al. [14] Combined SLE All Jan 1, 1966 41.8
Michet et al. [10] Discoid lupus erythematosus All Jan 1, 1980 27.6 (14.1–41.1)
Durosaro et al. [15] CLE All Jan 1, 2006 73.2 (58.3–88.2)
Jarukitsopa et al. [13] CLE All Jan 1, 2006 70.4 (55.9–84.8)

CLE = Cutaneous lupus erythematosus. Figures in parentheses indicate 95% confidence intervals. Prevalence estimate: the prevalence is a point prevalence if it was reported for a specific point in time (i.e. a specific day and year), but the prevalence is a period prevalence if it was reported for a specified period (e.g. months or years). In Nobrega et al. [14], combined SLE is defined as classic SLE (positive LE cell test and ≥3 major systemic manifestations of LE) plus rheumatoid arthritis with LE (previous rheumatoid arthritis with positive LE cell test and ≥3 major systemic manifestations of LE). As for Durosaro et al. [15] and Jarukitsopa et al. [13], both studies reported the point prevalence of cutaneous lupus erythematosus for the Olmsted County population in January 2006. Differences in these prevalences are due to differences in the methodology used in defining the denominator and in adjusting the population. Moreover, these prevalence estimates for cutaneous lupus erythematosus are underestimates since they were derived from incident cases in Olmsted County from 1965 to 2002.